- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2, Placebo, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI, Combination (Bivalent) BNT162b2 and BNT162b2 OMI
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 16,372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 139
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 99 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 190
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza, Human, SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV, Normal saline placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 644 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 30
- States / cities
- Lake Forest, California • Tustin, California • Walnut Creek, California + 22 more
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Interventions
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 570 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 27
- States / cities
- Anaheim, California • Walnut Creek, California • Coral Gables, Florida + 21 more
- Conditions
- Meningitis, Meningococcal
- Interventions
- Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 2 Months to 2 Months
- Enrollment
- 4,545 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 53
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1283, mRNA-1273
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 13
- States / cities
- Ontario, California • Miami, Florida • Miami Lakes, Florida + 9 more
- Conditions
- SARS-CoV-2, Influenza
- Interventions
- mRNA-1073, mRNA-1010, mRNA-1273, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 14
- States / cities
- Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more
- Conditions
- Healthy
- Interventions
- MEDI-560, Placebo
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Month to 11 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 23
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Madera, California + 20 more
- Conditions
- Influenza
- Interventions
- FluBlok Influenza Vaccination, TIV (Fluzone) Influenza Vaccination
- Biological
- Lead sponsor
- Protein Sciences Corporation
- Industry
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 602 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 5
- States / cities
- Fresno, California • Hayward, California • Roseville, California + 2 more
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
- Interventions
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 15 Months
- Enrollment
- 852 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 49
- States / cities
- Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more
- Conditions
- HIV Infections
- Interventions
- gp160 Vaccine (Immuno-AG)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1994
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Rochester, New York • Nashville, Tennessee
- Conditions
- HIV Infections
- Interventions
- HIVAC-1e, gp160 Vaccine (MicroGeneSys)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1992
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Seattle, Washington
- Conditions
- Hepatitis B
- Interventions
- 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 4
- States / cities
- Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
- Conditions
- Hepatitis B
- Interventions
- Hepatitis B Vaccine (Recombinant)
- Biological
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
- Interventions
- Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
- Conditions
- COVID-19 Vaccines
- Interventions
- UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine, Sinopharm BIBP
- Biological
- Lead sponsor
- Vaxxinity, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 944 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Brownsville, Texas
- Conditions
- Influenza Immunization, Healthy Volunteers
- Interventions
- Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine, Quadrivalent Recombinant Influenza Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 908 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 11
- States / cities
- San Diego, California • Hialeah, Florida • Hollywood, Florida + 8 more
- Conditions
- COVID-19, SARS-COV-2 Infection
- Interventions
- BNT162b2 (2025/2026 formulation)
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 27
- States / cities
- Palo Alto, California • San Diego, California • Homestead, Florida + 21 more
- Conditions
- HIV Infections, HIV Seronegativity
- Interventions
- gp160 Vaccine (Immuno-AG)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1997
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Seattle, Washington
- Conditions
- Influenza, Human, COVID-19
- Interventions
- Comirnaty, Quadrivalent Influenza Vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,442,996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ebola Virus Disease, Marburg Virus Disease
- Interventions
- cAd3-Marburg, cAd3-EBO-S
- Biological
- Lead sponsor
- Albert B. Sabin Vaccine Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Herpes Simplex Type 2
- Interventions
- HerpV and QS-21, Placebo
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Portland, Oregon • Houston, Texas • Seattle, Washington
- Conditions
- HIV Infections
- Interventions
- Hepatitis B Vaccine (Recombinant), gp160 Vaccine (MicroGeneSys)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1991
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
- Biological
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
- Biological
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts